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Purpose: Albinism is a group of genetic disorders, showing a broad spectrum of different phenotypes. The purpose of
this study was to screen known candidate genes for oculocutaneous albinism (OCA) and ocular albinism (OA) mutations
in Indian patients.
Methods: Blood samples were collected from 23 probands and 13 affected family members from 23 genetically unrelated
Indian families (22 diagnosed as OCA and 1 diagnosed as OA) and analyzed by bidirectional DNA sequencing of the
classic OCA genes— tyrosinase (TYR, or oculocutaneous albinism IA), pink eyed dilution (P; or oculocutaneous albinism
II (OCA2]), tyrosinase-related protein 1 (TYRP1), solute carrier family 45, member 2 (SLC45A2; or membrane-associated
transporter protein [MATP])—and the OA1 gene, G protein-coupled receptor 143 (GPR143).
Results: Three missense mutations, c. 715 C>T (R239W), c. 896 G>A (R299H), c.1255 G>A (G419R), and one
termination c. 832 C>T (R278X), were identified in TYR, as well as one novel mutation, c.1453 G>A (G485R) in P. One
novel single nucleotide polymorphism (SNP) was identified in both TYR and P; few reported SNPs were identified. The
G>A base substitution caused relatively conservative amino acid changes, which altered glycine to arginine residues within
the topological domain. The novel OCA2 mutation was not present in 100 control samples. This study identified two
probands carrying mutations alone, 16 probands carrying SNPs alone, 4 probands carrying both mutations and SNPs and
only one proband carrying neither mutations nor SNPs.
Conclusions: Although sequence analysis was performed with all five candidate genes, only four (17.39%) of the 23
probands showed mutations in TYR and 2 probands (8.69%) showed an unreported novel mutation in P. Genetic counseling
for phenotypical diagnosis and genetic mutation screening of these genes will help to minimize the incidence of OCA and
OA in future generations.
Albinism is an autosomal recessive inherited condition
present at birth. The phenotype ranges from a complete lack
of  pigmentation  in  the  skin,  hair  and  iris,  called
oculocutaneous albinism (OCA), or a lack of pigmentation in
the  iris  alone,  termed  ocular  albinism  (OA).  Several
independent defects can cause albinism including a complete
lack of melanocytes or few pigment cells, interference in the
migration of the cells to their proper location during embryo
development, and failure of the cells to produce melanin due
to  a  lack  of  tyrosinase  or  abnormalities  within  the  cells.
Albinism  is  associated  with  severe  photosensitivity  to
ultraviolet radiation and characteristic abnormalities in the
visual system include reduced vision, nystagmus, macular/
foveal hypoplasia, misrouting of optic fibers at the chiasm,
and greatly decreased visual acuity.
Melanin, a dark pigment, plays an important role in the
eyes and brain; it occurs in two forms-black-brown known as
Correspondence to: Dr. P. Sundaresan, Senior Scientist, Department
of Genetics, Dr. G. Venkataswamy Eye Research Institute, Aravind
Medical Research Foundation, Aravind Eye Hospital, No-1, Anna
Nagar,  Madurai  –  625  020,  Tamil  Nadu,  India;  Phone:
91-452-4356100;  FAX:  91-452-2530984;
email:sundar@aravind.org
eumelanin and yellow-red known as pheomelanin. Both forms
are dependent on the activity of the tyrosinase (TYR) gene
(mutations  in  TYR  are  responsible  for  OCA1;  OMIM
203100). This gene, which is a copper-containing enzyme
located  on  chromosome  11q14.3  [1],  is  expressed  in
melanocytes  and  controls  the  major  steps  in  pigment
production.
Mutations  in  the  pink  eyed  dilution  gene  (P;  or
oculocutaneous albinism II [OCA2]) gene (OMIM 203200)
cause the OCA type 2 phenotype [2]. The OCA2 protein is
important for normal biogenesis of melanosomes [3,4] and
normal  processing  and  transport  of  melanosomal  proteins
such as TYR and tyrosinase-related protein 1 (TYRP1) [5,6].
It  is  thought  to  control  the  melanosomal  pH  value,  thus,
regulating TYR activity and melanosomal distribution [7-9].
OCA type 3 (OMIM 203290) is caused by mutations in
TYRP1, which is located on chromosome 9p23 [10]. The
protein, which is encoded by the brown locus, exhibits more
than 50% sequence identity with tyrosinase [11] and shows
some tyrosine hydroxylase activity; it may specifically act as
5,6-dihydroxyindole-2-carboxylic  acid  (DHICA)  oxidase
[12,13].
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1515Human solute carrier family 45, member 2 (SLC45A2/
membrane-associated transporter protein [MATP]) (OMIM
606574)—a  novel  malignant  melanoma-associated  gene
mapping to chromosomal 5p13.3 located in the melanosomal
membrane— probably functions as a membrane transporter
directing melanosomal protein traffic and other substances to
melanosomes [14,15].
Ocular albinism is caused by mutations in the ocular
albinism  I  (OA1;  or  G  protein-coupled  receptor  143
[GPR143]) gene (OMIM 300500). The protein product is
thought to be a melanosomal transmembrane protein [16].
OA1 is expressed in eye and epidermal melanocytes.
We  present  a  molecular  analysis  of  TYR,  P,  TYRP1,
MATP and GPR143, well known candidate genes for OCA
and  OA1  types,  in  23  (OCA-22  and  OA-1)  South  Indian
families (36 affected individuals with a positive history of
albinism).
METHODS
The study group: All participants (16 consanguineous and 7
non-consanguineous  familial  cases)  were  referred  for
molecular analysis by investigators from the Paediatric Clinic,
Aravind  Eye  Hospital,  Madurai,  Tamil  Nadu  and  Netra
Niramay  Niketan,  Vivekananda  Mission  Asram,
Chaitanyapur, West Bengal, India. The study adhered to the
Declaration  of  Helsinki  criteria  and  was  approved  by  the
institutional review board; an informed consent form was
obtained from each patient following an explanation of the
nature of the study. All the patients were diagnosed using the
ophthalmologic examinations detailed in Table 1. Data were
also obtained on other ocular conditions such as cataracts,
glaucoma, and retinal disease. The controls were selected
from 100 healthy individuals with no family history of ocular
abnormalities.
Preparation of genomic DNA: Approximately 5 ml of blood
was collected from each proband and members of their family.
Genomic  DNA  was  prepared  from  peripheral  blood
leukocytes using the salting-out method [17] and dissolved in
TE buffer (1 M Tris-pH 8.0; 0.5 M EDTA-pH 8.0). The DNA
was quantified using a Nano spectrophotometer (NanoDrop
Technologies,  Inc.Wilmington,  DL)  and  subjected  to
mutation screening analysis.
PCR amplification of genomic DNA: The genomic DNA was
amplified  using  PCR  (MJ  Research-PTC-200;  Peltier
Thermal  cycles,  Taunton,  MA;  Eppendorf  Mastercycler,
Westbury, NY) containing 50 ng of genomic DNA, 0.2 mM
concentration  of  each  primer,  200  mM  dNTPS  (Medox,
Biotech PVT.LTD, Chennai, India), 10 mM Tris-HCL (pH
8.3), 50 mM KCL, 1.5 mM Mgcl2 and 0.2 U of Taq DNA
polymerase (Sigma Aldrich, St. Louis, MO) in 20 ul volume
reaction  mix.  The  primer  sequences  for  the  intron-exon
boundaries and exonic regions were selected for the TYR
[18,19], P [20], TYRP1 [21], MATP [22], and GPR143 [23]
genes. Primer sequences are presented in Table 2. For all
amplicons, the genomic DNA was denatured at 94 °C for 5
min followed by 28 cycles of denaturation at 94 °C for 30 s;
the annealing temperature differed according to the Tm value
of each primer set, extension at 72 °C for 45 s, and final
extension at 72 °C for 10 min.
Mutational analysis: The PCR products were purified using
the gel elution kit method (Bio Basic Inc., Toronto, Canada).
Bi-directional DNA sequencing for known candidate genes of
OCA and OA (for exon- intron boundaries and exonic regions)
was  performed  for  all  the  probands  and  affected  family
members. Big dye termination chemistry was employed (3130
Genetic Analyzer; Applied Biosystems, Foster City, CA). The
sequencing results were compared to the gene sequences of
TYR, P, TYRP1, MATP, and GPR143 using Finch TV and
Chromas softwares.
The presence of novel mutations that were identified in
the probands was examined in 100 unrelated healthy persons
with  normal  phenotypes  to  exclude  the  possibility  of
polymorphisms.  All  the  mutations  were  reconfirmed  by
sequencing with the new PCR product. Heterozygous patients
were systematically resequenced to ensure that the screening
had not overlooked mutations. To compare the impact of these
genes on 22 OCA samples and 1 OA sample, OCA and OA
known  candidate  gene  screening  was  performed  for  all
samples.
Among the families selected, each affected individual
(proband) was analyzed for sequence changes in the selected
candidate genes. If a sequence change was identified that
resulted in alterations in the amino acid sequence in the protein
encoded by the gene, the rest of the family members were
analyzed for co-segregation of the genotype.
Evolutionary conservation of human variant amino acid
residues was evaluated using Expasy tools by alignment to pig
(Sus scrofa), mouse (Mus musculus), oryla (Oryzias latipes),
astfa  (Astyanax  fasciatus),  and  nemve  (Nematostella
vectensis).
Restriction  enzyme  cleavage  analysis:  The  presence  or
absence  of  a  restriction  site  was  used  to  detect  the  co-
segregation of sequence variations in family members and the
control population. Free online software (Insilico) was used
to  identify  the  appropriate  restriction  enzyme.  Restriction
digestion  of  PCR  products  was  performed  as  per  the
recommendations  of  the  respective  manufacturers  (New
England BioLabs, Beverly, MA). For 1 ug of DNA, 10 units
of  restriction  enzyme  was  used  and  incubated  at  the
recommended temperature overnight and analyzed using 2%
pre-stained agarose gel.
RESULTS
Clinical criteria: A summary of the available clinical data are
given in Table 1. Few families alone lack the clinical details
that include visual acuity and type of refraction error. Most
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1516TABLE 2. PCR PRIMER SEQUENCES FOR TYR, P, TYRP1, MATP, AND GPR143.
PCR primers PCR primer sequence (5’-3’)
Melting temperature
(°C)
PCR product
size (bp)
Tyrosinase (Tyr) gene [18,19]
Exon 1-1 F-CAAACTGAAATTCAATAACATATAAG 63 678
  R-GTGGACAGCATTCCTTCTCC    
Exon 1-2 F-TTCAGAGGATGAAAGCTTAAGATAAA 62 521
  R-CGTCTCTCTGTGCAGTTTGG    
Exon 1-3 F-CTGGCCATTTCCCTAGAGC 59 605
  R-CCACCGCAACAAGAAGAGTC    
Exon 1-4 F-CATCTTCGATTTGAGTGCCC 60 514
  R-CCCTGCCTGAAGAAGTGATT    
Exon 1-5 F-CACCCATGTTTAACGACATCA 59 225
  R-GCCAGTCCCAATATGGAATA    
Exon 1-6 F-GACTCTTCTTGTTGCGGTGG 60 252
  R-CCCTGCCTGAAGAAGTGATT    
Exon 2 F-CCAACATTTCTGCCTTCTCC 60 442
  R-TCAGCTAGGGTCATTGTCGAT    
Exon 3 F-AGTTATAAATCAAATGGGATAATC A 60 296
  R-ACATTTGATAGGCACCCTCT    
Exon 4 F-CTGTTTCCAATTTAGTTTTATAC 55 790
   R-TACAAAATGGCCTATGTTAAGC    
Exon 5 F-TGTCTACTCCAAAGGACTGT 59 924
  R-GGCACTTAGCTGGATGTGTT    
Pink eyed dilution (P) gene [20]
Exon 1 F-GAGTTCTTACTTCGA 52 172
  R-TAAACCCTCCCTGCCTGTTC    
Exon 2 F-GGTGCAAACGTTAGTCTCAG 60 359
  R-CCAATCTGTGTGAAGTCCAC    
Exon 3 F-CTGGGAACACATACATTATT 56 209
  R-GTGCAATGCTCAGAAACTCT    
Exon 4 F-AAGCTTGCTTTGTAGCCATT 65 300
  R-CGATGTGCGGCCACCGCTGC    
Exon 5 F-GAAAAGTGTCTGAGTCTGGC 62 177
  R-GTCCCGAAGGTGCCTGGGTT    
Exon 6 F-ATTTATACCTTACTGCTCTC 58 183
  R-TTTCAGATCTCAGCCAGGCG    
Exon 7 F-GGACATGGGGTTTCTCCTGT 59 264
  R-TGAGATGAAATGAGATTTCAC    
Exon 8 F-AGATCCCAGATGGTGTCTCA 59 213
  R-AGGTCAGACTCCTTTAAACG    
Exon 9 F-AGAGGGAGGTCCCCTAACTG 63 272
  R-ATCTCAAGCCTCCCTGACTG    
Exon 10 F-CTTTCGTGTGTGCTAACTCC 57 195
  R-ACATCTTTGAGCTGACATCC    
Exon 11 F-GCAGCGCTTCATTAGGCTCA 64 201
  R-GGCCAGAGAAGGCCCGGTTA    
Exon 12 F-GTCGTTTTAATATGGTGGCC 56 256
  R-CCTGCAGAAGCAACCTTTA    
Exon 13 F-GCCTCTGTTCTACGAGCCTG 63 231
  R-TGCCAGAACCTGGCCGCAA    
Exon 14 F-TTCACGATGTGTATAGTGGG 59 239
  R-AAGTGGAGGTGTGCGTTTAC    
Exon 15 F-GATTACAGGCGTGAGCCACC 61 293
  R-ACCCATCAACAGATACTTCC    
Exon 16 F-GAGGGTGTTGCTGATATCTG 60 260
  R-GAATGTTCTGCTGCACACCA    
Exon 17 F-AGGCTCCAAGTCACAGACCG 62 219
  R-CTTCTTGGAGAAGTGAATCAG    
Exon 18 F-AGTTGCGTAGGTTATGACAC 58 235
  R-CCCATCCAGAATGTGACAAA    
Exon 19 F-GTTATGTATTTGCAGCCCCT 58 197
  R-AATCCACCAAATACAATTGA    
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PCR primers PCR primer sequence (5’-3’)
Melting temperature
(°C)
PCR product
size (bp)
Exon 20 F-GAATCGGTGTGTTAACAGTG 59 266
  R-GTAGGCTTTCTTCATTCACC    
Exon 21 F-GCCTACCTTATGTTCACGTC 58 212
  R-AATCAAAGAACAGTGGCTGG    
Exon 22 F-TGGTGGGTCTGACCCTAAGT 59 219
  R-AGGCTATGTCCAGGCTAAAG    
Exon 23 F-ACAGTATGGCAGCTTCTCTG 59 229
  R-ACTAACTGTTGCTTTGGGCT    
Exon 24 F-GAGAACAGAAGCTTACCACC 55 204
  R-GCTTAGGAACTAGACAGTTTA    
Exon 25 F-CGTATCTCATGAGCTTATCC 58 574
  R-AGCATACAATTTGAATGCTG    
Tyrosinase-related protein 1 (TYRP1) gene [21]
Exon 1 F-AGAAGTTCATCAGAGACATC 50 189
  R-TCACCATCATTAATTACATT    
Exon 2 F-CGTGCTTCAGTCTTCTCTACA 59 490
  R-GCAAGGACTTATGAACTCATTC    
Exon 3 F-CGCAAGGCAGATGTTTTCATG 59 416
  R-AAGGCATCTTGTCTGTAAAGA    
Exon 4 F-AGACCAAACAGAAATGAATA 47 305
  R-AAATTCTGACTCCAAGCTATC    
Exon 5 F-AAAGAGCGACAATAAGAACTC 50 319
  R-AAAGCCTTCTCAAAGAAACTT    
Exon 6 F-TTGCTATTACCTGGAAAAGTG 51 275
  R-TGCAAAAAGCATATGAAAATG    
Exon 7 F-ATACGTTGTCTTTGGAATAAT 51 252
  R-ATACCGTGATTACTCTACTTG    
Exon 8 F-TGTCCACTTTTTGGTGATAAC 50 323
  R-ATTCAACCAGGTGGTTTTGTG    
Membrane-associated transporter protein (MATP) gene [22]
Exon 1-1 F-AGGCTCCACGTCAAATCCAG 63 260
  R-GGTCACATACGCTGCCTCCA    
Exon 1-2 F-CAGACTCATCATGCACAGCA 58 252
  R-ATGCCCACGAGCATCATGAC    
Exon 1-3 F-CAGCATTGTGTGGTTCCTCA 58 261
  R-GGTCAAACACATGAACATCCTC    
Exon 2 F-AACGCGGATGATTCTAAAACAGGA 65 280
  R-CTCATTGTCTGGGGAGCTGA    
Exon 3-1 F-GGGAGTGTCTATGCATGAGG 65 324
  R-GATAGAACCATACTCGTACATTCC    
Exon 3-2 F-GCCCCACTTACAGAGGTTGC 63 224
  R-CAACAAAGAGCAAGAATATTTTCCCTTG    
Exon 4 F-AGCTGGCTGAGTTTCTGCAG 62 265
  R-CCTCAACAGGTGTTAATGGAGG    
Exon 5 F-AGAGGTGGAGAAGCAGAGTG 64 236
  R-GAAGACATCCTTAGGAGAGAG    
Exon 6 F-ATGAGGCACTGCCAGCTGTA 64 286
  R-CCCAAGGCAGAGGTTCAATG    
Exon 7 F-GCCCTAAATGACAGTTCCTTG 58 326
  R-TGTGCTTCACTGTCTCTGAG    
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1518patients  exhibited  hypopigmented  iris,  nystagmus,
photophobia,  refractive  error  with  combined  myopic  or
hypermetropic astigmatism, and albinotic fundus with foveal
hypoplasia.
Identification  of  mutations:  Bi-directional  DNA  sequence
analysis revealed four mutations (R239W, R278X, R299H,
and G419R) in OCA type I (TYR) and one novel mutation
(G485R) in OCA type II (P) among 23 probands and 13
affected individuals from the 23 familial cases (recruited from
80 families). As shown in Table 3, four probands showed
mutations in TYR (17.39%), and two probands expressed the
same novel mutation in OCA2 (8.69%).
In  family  55,  11  members  (two  affected  and  nine
unaffected)  underwent  bi-directional  DNA  sequencing
analysis. The analysis revealed that the proband (55–1) was
homozygous for a c.715C>T mutation. This mutation was also
identified  as  homozygous  in  the  proband’s  maternal
grandmother who had albinism. Both parents showing the
normal phenotype were heterozygous for the mutation. The
genotype  status  was  further  confirmed  by  SsiI  restriction
enzyme digestion of exon 2 PCR product amplified from the
DNA of the proband’s unaffected parents. Both parents were
confirmed to be heterozygous for the c.715C>T mutation. The
maternal grandfather and grandmother were heterozygous and
mutant homozygous, respectively. The remaining unaffected
members of the family exhibited a wild type of the mutation.
The  wild  type  sample  following  SsiI  restriction  enzyme
digestion revealed three (166 bp, 72 bp, and 14 bp) fragments,
whereas the mutant sample showed only two fragments (238
bp and 14 bp), as a result of the loss of one SsiI digestion site
(data not shown).
In family 35, base changes in the c.832C>T mutation
were observed in both alleles, that codon results (R278X)
termination  of  protein  synthesis  in  proband  (35–1).  Bi-
directional sequence analysis of exon 2 PCR-amplified DNA
of the proband’s unaffected mother and maternal grandmother
revealed the carrier status of (R278X) stop codon.
In family 40, a c.896G>A transition was identified on
both  alleles  in  the  proband  (40–1),  and  the  proband’s
unaffected father was heterozygous for the stop codon with
carrier genotype.
Similarly in family 24, the c.1255G>A transition was
identified in exon 4 of the proband (24–1) as homozygous; no
other  family  members  were  willing  to  undergo  further
analysis.
Interestingly, the probands from families 11 (Figure 1A;
V:1) and 52 (Figure 1B; VII:1) were found to be homozygous
for the novel mutation c.1453G>A identified in exon 14 of the
P gene, responsible for OCA type II. One hundred individuals
with normal phenotypes were screened for this novel mutation
to exclude the possibility of polymorphisms. The degree of
consanguinity in both families was high, with both parents
marrying  first-degree  relatives.  The  family  members  of
pedigree 11 were not willing to participate in this study so no
further analysis could be undertaken. We, therefore, have no
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TABLE 2. CONTINUED.
PCR primers PCR primer sequence (5’-3’)
Melting temperature
(°C)
PCR product
size (bp)
G protein-coupled receptor 143 (GPR143) gene [23]
Exon 1-1 F-GAGCCTGGCTCTACTGCAGGCGCT 64 250
  R-TGCCCAGGCAGAGCGCGTGGAAGG    
Exon 1-2 F-AGCCACGCAGCTCGTGCTGAGCTTCCAGCC 68 250
  R-CCCAGGCGCTGATCAGATTCCAACCCGCG    
Exon 2 F-TCATTTTTCCAAAGCAAGAAGTCAGC 66 293
  R-GCAGGACGTGAGAACCTGCATT    
Exon 3 F-GTCTACCCTGCCGTCTCAAGGATG 66 248
  R-CGCTCAGTGCCATCTCTTATCTTCC    
Exon 4 F-GTTCCAGGCAGGCCTCTGTGC 68 229
  R-GGCTCATGTATTCCCTGCAAGACAAC    
Exon 5 F-TTTCCCTTTTTGTTCTCATCCTCTTA 63 299
  R-AGGACAACATGTGTCACTGTCTGAG    
Exon 6 F-ACCTGCTTCCATTGCCTTCTCTGTC 68 288
  R-CTTCCCTTTGGAACTTCTGGTCACG    
Exon 7 F-GAAATTCTTCTCTGACTCTCCAGCATT 63 278
  R-TGACAGAGTGAGACCTTGTCTCTGA    
Exon 8 F-ATGGTCCCTTCCAAGCGAGTCC 68 492
  R-TCACATGAGAGGTGCTGCTGAACAC    
Exon 9 F-TGAAAAACTCCATGCACTGAATACT 61 597
  R-TGCATAACTGTACATGTATTTATTTTCTTTTG    proof of G485R inheritance in family 11 alone. However, in
family  52  the  diseased  allele  was  heterozygous  in  the
proband’s unaffected father, mother, maternal grandmother,
and first younger sister.
Identification  of  polymorphisms:  Although  bi-directional
DNA sequencing revealed five different polymorphisms in
the  exon,  intron,  and  3′UTR  region  of  TYR,  P,  TYRP1,
MATP, and GPR143, no pathological gene mutations were
detected  among  the  selected  candidate  genes  in  a  few
probands.  Thus,  we  report  on  the  polymorphisms  we
identified. In the study group, two probands (55–1, 49–1)
exhibited an I222V polymorphism and one proband (32–1)
had I222V and R402Q polymorphisms in TYR (13.04%). All
three  probands  exhibited  heterozygous  patterns  for  these
SNPs in the regions analyzed. Both of the SNPs in TYR were
not observed in any of the control samples. In P, the SNP
IVSXX+4  A/G  was  observed  in  nine  different  probands
(39.13%) in the heterozygous form; similarly, heterozygosity
was observed in three of the 100 controls used in the analysis.
In TYRP1, proband 25–1 (4.34%) alone showed an R87R
polymorphism in one allele; this SNP was not identified in the
100  healthy  controls.  In  MATP,  13  different  (56.52%)
probands exhibited polymorphisms. Eleven probands carried
the SNP T329T (two probands were homozygous and nine
probands were heterozygous). This SNP was also detected in
16 of the 100 controls. Apart from this polymorphism one
proband 42-1 carried the SNP, Leu374Phe, in exon-5 and
rs45552240 (SNP) was observed in 32-1 on exon 7. Similarly,
nine different (39.13%) probands exhibited IVSV1+10C/G
polymorphisms in GPR143 (eight probands from OCA-24–1;
46–1; 49–1; 58–1; 54–1; 21–1; 32–1; 52–1 and one proband
from OA-50–1). Table 3 represents a list of the mutations and
polymorphisms.
DISCUSSION
There is an increased awareness of genetic diseases in all of
the races. Identification of mutations in candidate genes will
facilitate  DNA-based  diagnosis  of  albinism.  Molecular
analysis  of  pathological  mutations  to  reveal  the  origin  of
mutated alleles in a study population is useful under certain
circumstances such as understanding the nature and severity
of mutations to deliver genetic counseling. We identified four
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TABLE 3. MUTATIONS AND POLYMORPHISMS IN TYR, P, TYRP1, MATP, AND GPR143.
        Mutations  
Gene Patient ID Exon Intron Alteration in
c.DNA
Alteration in protein SNPs
TYR 55–1 1   c. 715 C>T R239W I222V*±
  35–1 2   c. 832 C>T R278X  
  40–1 2   c. 896 G>A R299H  
  24–1 4   c.1255 G>A G419R  
  49–1 1       I222V*±
  32–1 1 & 4       I222V*±& R402Q ±
P 11–1, 52–1 14   c.1453 G>A G485R#  
  17–1, 21–1, 24–
1, 35–1, 46–1,
49–1, 54–1, 55–
1, 58–1 (H)
  20     IVSXX+4 A/G*
TYRP1 25–1 2       Arg87Arg
MATP 16–1, 44–1 (h)          
  5–1, 14–1, 17–
1, 21–1, 35–1,
41–1, 52–1, 58–
1, 62–1 (H)
4       Thr329Thr
  42–1 (h) 5       Leu374Phe
  32–1 (H) 7               rs45552240
GPR143 50–1 (h)          
  24–1, 46–1, 49–
1, 58–1 (h)
         
  54–1, 21–1, 32–
1, 52–1 (H)
  6     IVSV1+10C/G
In the table, # indicates a novel homozygous mutation (PMID: 19309806); the asterisk indicates a novel polymorphism; (H)
indicates Heterozygous; and (h) indicates - Homozygous. Among the 23 Albinism families, the probands from 22 OCA families
shows either mutation or polymorphism except the proband from family 39–1, In GPR143, one SNP was observed on the OA
proband alone. Among the candidate gene analysis, a novel mutant was observed on OCA2 that was absent in 100 alleles of
ethnically matched controls and could represent potential amino acid change in the gene.known mutations in TYR and one novel mutation in P in 23
unrelated families. The clinical categorization of an individual
has become more unique and complex. Clinical references are
useful and are sufficiently precise for initial diagnosis and
family  counseling.  Accurate  diagnosis  of  most  genetic
disorders is only possible with candidate gene analysis. Of the
four mutations identified in the patients with albinism, three
were  missense  and  one  was  a  nonsense  (termination)
mutation. These mutations were mainly clustered in exons 1,
2, and 4 (Table 3) of TYR. In the entire proband sample, four
of  23  (17.39%)  individuals  were  homozygous  for  a  TYR
mutation; consanguinity was associated with two of these four
mutations.
The R239W missense substitution in TYR in a patient
(55–1) from family 55 with tyrosinase-negative OCA was
previously  reported  in  Japanese  patients,100%,  6.25%,
respectively [24,25], and Chinese patients, 0.83% [26]. The
4.34% frequency we identified in our study group does not
match any of these earlier findings.
In proband 35–1, the exon 2 direct sequence reveals a
homozygous  change,  c.832C>T,  that  would  create  a
premature stop codon, R278X, resulting in a truncated and
completely inactive enzyme lacking one potential copper-
binding  region.  This  mutation  was  previously  reported  in
various ethnic groups Guayanan, 12.5% [27]; Jewish, 2.6%
[7]; Japanese, 100%, 12.5%, 22.2%, respectively [8,25,28];
European, 2.5% [26]; Mexican, 0.83% [26]; Indian, 0.83%
[26]; Syrian, 0.83% [26]; Eastern Indian, 25%, 100%, 8.3%,
respectively  [18,29,30];  Indian,  80%  [31];  and  Chinese,
18.75% [32]. The frequency of the mutation in our study,
4.34%, does not correlate with that reported in the previous
studies. The fact that c.832C>T has been reported in different
ethnic  groups  suggests  that  c.832C>T  may  represent  a
mutation hot spot in different populations.
One  missense  substitution,  R299H,  was  detected  in
proband 40–1 despite the fact that the child was the offspring
of  a  non-consanguineous  marriage.  The  heterozygous
missense mutation was present in the proband’s unaffected
father. The R299H substitution has been observed previously
in Caucasian, 12.5% [33]; Arab-Christian, 2.6%, 1.6%, 3.3%,
respectively [7,26,34]; and Chinese, 18.75% [32] populations.
We detected a 4.34% frequency of the R299H mutation, an
approximate match to that reported earlier in Arab-Christian
populations [34]. The G419R mutation was identified in exon
4  of  proband  24–1.  This  pathological  mutation  has  been
previously reported in Indo-Pakistani, 25% [27]; Caucasian,
0.83% [26]; Pakistani, 0.83% [26]; Indian, 20% [31] and
South-Indian,  16.6%  [30]  populations.  Once  more,  the
frequency, 4.34%, of the mutation in our study patient showed
no correlation with previous findings.
We identified a novel missense mutation, c.1453G >A
(G485R) in P of two genetically unrelated patients. In family
52, the proband’s parents, maternal grandmother and first
younger sister are carriers of the mutation. The finding sheds
new  light  on  the  P  gene  mutation  and  highlights  the
importance of analyzing this gene in Indian patients. Our
results also indicate that the frequency of mutations in the
OCA2 gene in Indian patients is to some extent comparable
to that seen in Caucasian patients [35]. The presence of this
mutation in the OCA2 gene is the first report in an Indian
patient [36].) A novel c.1454G>T (p.G485V) mutation has
been recently reported in a Danish population [37] in the same
codon.
Figure 1. Pedigree and chromatogram of novel mutation Gly485Arg. A: Pedigree obtained from family 11. B: Pedigree obtained from family
52. C: Normal genotype from control samples. D: Heterozygous genotype from unaffected father (V:3), mother (VI:1), maternal grandmother
(V:2), and first younger sister (VII:2). E: Mutant genotype from both Probands (V:1) and (VII:1) from family 11 and 52. F: Evolutionary
conservation of Gly485Arg among the other related mammalian species. The amino acid residue glycine in the 485th position shown in red
are evolutionary conserved.
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(I222V) in TYR in three different patients (32–1, 49–1, 55–1).
The SNP rs34878847 (c.665T>C) has been reported in the
same codon. In family 32, the proband 32–1 and his affected
father  were  heterozygous  for  a  c.1205G>A  transition,
(R402Q), in exon 4 of TYR. The heterozygosity was confirmed
using Hpy188I RFLP analysis, in which mutation results in
the loss of one restriction site; digestion reveals 368 bp, 182
bp, 150 bp, 50 bp,and 41 bp products in wild-type samples,
whereas in heterozygous individuals it produces 368 bp, 22
3bp, 182 bp, 150 bp, 50 bp, and 41 bp fragments. In both
instances, products below 100 bp were not clearly visible in
agarose  gel  electrophoresis  (data  not  shown).  R402Q,  a
common  non-  pathological  polymorphism  of  the  human
tyrosinase gene, was previously reported in Caucasians [38].
Here, the substitution of glutamine for arginine at codon 402
results in moderate thermoinstability of the corresponding
tyrosinase polypeptide [38].
One  novel  intronic  SNP  IVSXX+4  A/G  was
heterozygous  in  P  from  nine  different  probands.  The
rs34509359  (R87R)  SNP  has  been  previously  reported  in
TYRP1 [39]. We detected the same SNP in patient 25–1 as
heterozygous.
In MATP, we identified a common synonymous SNP
rs2287949,  (T329T),  in  exon  4  as  homozygous  in  two
different patients and heterozygous in another nine patients.
In  the  same  gene,  a  non-synonymous  SNP  rs16891982,
(L374F), in exon 5 was homozygous in one patient (Table 3).
Both these SNPs have been previously reported in a Turkish
population  and  an  East  Indian  population  [40,41].  L374
significantly increases the possibility of having black hair and,
thus, may be considered a future marker for the prediction of
black hair color [42]. In the MATP coding sequence, one
3′UTR SNP, rs45552240, was heterozygous in patient 32–1.
In  GPR143,  the  intronic  SNP  rs3788938  was
heterozygous in four patients and homozygous in five others.
Taken together, our results indicate that six probands
harbored five mutations (four reported and one novel in two
probands) and that more than half of affected individuals who
were tested (29 among 36) exhibited no apparent pathological
mutations  in  the  selected  candidate  genes.  However,
homozygous  and  heterozygous  polymorphisms  were
distributed among the selected candidate genes across most of
those with the disease, except one patient (39–1) who showed
normal  iris  pigmentation.  The  prevalence  of  inherited
ophthalmological diseases in our study is associated with the
high rate of consanguineous marriage that we observed. Our
study contributes to the development of mutation detection
methods  for  OCA  and  OA  in  South  Indian  families.  The
identification of prevalent or novel alterations in candidate
genes will shed new light on studies of expression analysis
and  may  reveal  alterations  in  mutated  alleles  suitable  for
further  functional  studies.  Further  analyses  are  needed  to
provide insight into the structure-function relationships of
mutations involved in the candidate genes for albinism.
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